Rakesh Jetly, MD: The Pursuit of Personalized Medicine for PTSD

Video

Dr. Rakesh Jetly is leading a new phase 2 study testing psychedelics in veterans with PTSD.

Post-traumatic stress disorder (PTSD) is all too common for veterans, with many struggling to find the right medications to treat the underlying disease.

Around half of patients with PTSD do not respond to the first treatment option, forcing clinicians to move down the line to find other suitable options.

However, researchers are now moving forward with a new study testing low-dose psychosubstances as a potential treatment for this patient population.

In an interview with HCPLive®, Rakesh Jetly, MD, Head of the Center of Excellence on Mental Health, said one of the goals of the phase 2 study will be not only to test the safety and efficacy of the treatment, but also identify how it could help patients in other areas of life.

Because much of what veterans go through during combat causes long-lasting pain issues, there is the potential this treatment can help reduce the amount of veteran patients dependent on opioids for pain relief.

Another byproduct of the study testing psychedelics in PTSD patients is researchers may learn more about the brain and why it responds to certain treatments but not others.

The study could be another piece to the puzzle as researchers begin to try to implement new personalized medicine regimens for patients.

Related Videos
Leesha Ellis-Cox: Steps to Closing the Bipolar Disorder Diagnosis Gap for Blacks
Daniel Greer, PharmD: Reduction in Rehospitalizations with Antipsychotic Injections for Schizophrenia
Understanding the Link Between Substance Use and Psychiatric Symptoms, with Randi Schuster, PhD
Andrew Miller, PhD: Inventor of KarXT Discusses Pivotal EMERGENT-2 Data
New Drug Application for MDMA-Assisted Therapy for PTSD Awaits FDA Approval
Reviewing 2023 with FDA Commissioner Robert M. Califf, MD
A Year of RSV Highs and Lows, with Tina Tan, MD
© 2024 MJH Life Sciences

All rights reserved.